Supplementary Tables. Cost–effectiveness and cost–benefit analysis of oliceridine in the treatment of acute pain

Supplementary Table 1. Estimated mean and median cost and length of stay (LOS) derived from the 2017 National Inpatient Sample-Healthcare Cost and Utilization Project (NIS-HCUP) dataset. <br>Supplementary Table 2. Estimated cost weights for opioid-induced respiratory depression events by type of surgery (in 2017 US dollars).<br>Supplementary Table 3. Health economic model cost weights for opioid-induced respiratory depression, vomiting, and somnolence inflated to 2020 US dollar costs.<br>Supplementary Table 4. Base model estimates: Summary of impact of sensitivity analyses on the base model estimates. <br>Supplementary Table 5. Oliceridine parameter values used in the Monte Carlo simulations (values for morphine parameters were similarly varied).<br>